ABSTRACT
The spread of intellectual property laws worldwide has imposed legal constraints on the sharing of innovations and cultural practices in a time when concepts and experiences progressively become forms of property. Examining the patent conflicts in the pharmaceutical sector, this research article explores the difficulties in juggling access to medication with the necessity for innovation. It looks at how countries like India, with rich histories in both Western and non-Western medical systems, negotiate the convoluted terrain of IP regulations shaped by World Trade Organisation and multinational businesses. The study looks at the consequences of India’s 2005 Patents (Amendment) Act, which was mandated by the TRIPS agreement of the WTO and required India to match its patent laws to a worldwide standard, therefore restricting the manufacturing of generic drugs. The study also tackles issues of biopiracy, in which international corporations profit from local and indigenous knowledge being used. The study offers a complete knowledge of the socioeconomic and legal difficulties in the pharmaceutical sector by means of an analysis of the interaction of national regulations, business interests, and worldwide agreements. It underlines the importance of a balanced strategy protecting public health and innovation as well as the part counter-efforts like the Access to Knowledge movement and Creative Commons licencing play in preserving a public domain for necessary drugs and knowledge.
Keywords:- Access to Medicine, Innovation, WTOM TRIPS, Generic Medicine, Public Interest.
INTRODUCTION
In our contemporary world, an increasing number of ideas and experiences are being transformed into forms of property. The expansion of intellectual property (IP) laws globally has resulted in numerous innovations and cultural practices being fenced off legally, restricting the free sharing of these creations. This new global regime of intellectual property protections has seen ownership claims over diverse entities such as yoga routines, genetically engineered animals, culinary traditions, and cultural practices. For instance, the cultural practices of Afro-Brazilians and the intricate French gastronomy have all been subjected to ownership claims, highlighting the far-reaching implications of this regime.
Furthermore, “the extension of familiar forms of intellectual property law, such as copyright and patent laws, has exacerbated the situation. Copyright laws now keep vast collections of films and literature out of the public domain, while new patent laws make it increasingly difficult to share medical knowledge and produce generic versions of essential medicines. Major contributors to this new regime include United States court decisions, multinational corporations, and the World Trade Organization. These entities have collectively turned knowledge that was once part of the public domain into the property of individuals, corporations, and specific communities.”
At the same time, counterefforts are underway to resist this monopolization of knowledge and innovation. “Movements such as Access to Knowledge, Creative Commons licensing, and programs like Doctors Without Borders’ Access to Essential Medicines struggle to keep artistic creations, medications, and scientific knowledge within the public realm. These efforts are crucial in ensuring that essential knowledge remains accessible to the broader public, rather than being confined within the proprietary boundaries set by powerful interests.”
India, in particular, has been a significant battleground in the global struggle over the ownership of pharmaceutical knowledge. “As a center of medical knowledge for centuries, India is home to several non-Western medical systems taught in colleges and practiced in hospitals. The country’s growing pharmaceutical sector also provides many of the world’s Western biomedical drugs. Over the past decade, as I discussed my research on patent controversies in India with people in the United States, I often encountered comments about Indian companies “stealing” products from US companies or “violating” patents by producing “copies” of patented medications.” However, these views often stemmed from a misunderstanding of the legal framework governing patents in India before the WTO implemented its global patent rules.
Before the WTO’s Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, each country crafted its own patent laws tailored to its unique priorities and concerns. India’s pre-WTO patent law included a provision that allowed for the patenting of processes for making a medication, but not the medical product itself. This meant that different companies could produce the same medicine if they could find a different manufacturing process. Consequently, Indian companies were free to create their versions of drugs patented elsewhere, covering a wide range of medications from antidepressants and AIDS treatments to erectile dysfunction drugs and statins like Pfizer’s Lipitor.
The Indian government introduced this product patent exception in 1970 to prevent monopoly control over essential medicines. Lawmakers recognized that medications, which have the potential to save lives and cure diseases, were fundamentally different from other inventions. In contrast, the United States had long protected medicines through product patents, aligning its laws closely with the interests of pharmaceutical corporations. This alignment has led to what some critics describe as frivolous patents on slight modifications of drugs, known as “me-too” drugs, which offer no significant increase in efficacy.
With the advent of the WTO and the implementation of TRIPS, member nations, including India, were required to conform to a standardized intellectual property regime modeled after the United States. This mandate compelled India to amend its patent laws to align with TRIPS by 2005, resulting in the passage of the 2005 Patents (Amendment) Act. While TRIPS limited the sharing of Western pharmaceutical knowledge and production by expanding patents, it also raised concerns about “biopiracy.” Biopiracy refers to the exploitation of local or indigenous knowledge to create commercial products for multinational companies.
Indigenous peoples and practitioners of non-Western medicine systems in countries like India and Brazil feared that multinational companies would exploit their knowledge of medicinal plants for commercial gain. For example, “the active ingredient in the plant Rauwolfia serpentina, used in Ayurveda to treat mental disorders, was isolated to create the first effective antipsychotic in Western psychiatry and subsequently patented. Similarly, curare, used by indigenous people in South America, was made into an anesthetic by a US company. These pharmaceutical innovations, developed by laboratories that later became part of Novartis and Bristol-Myers Squibb, illustrate the ongoing relevance of biopiracy concerns.”
Recent patent disputes involving multinational companies like Novartis and Bristol-Myers Squibb in India highlight the continued tensions between proprietary rights and access to essential medicines. Additionally, the issuance of US and European patents based on Indian knowledge of turmeric and neem tree properties underscores the pervasive influence of biopiracy. Legal scholar Ikechi Mgbeoji estimates that over one-quarter of modern drugs prescribed globally are derived directly from plant life forms, many of which originate from traditional knowledge.
As we navigate this complex terrain, it is crucial to critically examine and reform the current IP framework to better balance the interests of innovation and public health, ultimately fostering a more inclusive and equitable global health landscape.
RESEARCH METHODOLOGY
Examining legal concepts, statutes, and case laws pertaining to intellectual property—especially with an eye towards patents in pharmaceuticals—the doctrinal research process for this work follows It covers methodical analysis and interpretation of legal texts, statutes including the TRIPS Agreement of the WTO, and pertinent court rulings from nations such India and the United States. This strategy is to offer a thorough awareness of how legal frameworks affect the ownership, spread, and protection of pharmaceutical knowledge worldwide, therefore guiding debates on the balance between intellectual property rights and public health issues.
REVIEW OF LITERATURE
Halliburton, Murphy, 2017.
Halliburton writes on the junction of India’s changing intellectual property scene and pharmaceutical patents. It looks at how historically a centre of generic medication manufacture India adjusted to TRIPS global patent restrictions. Key judicial disputes such Novartis v. Union of India are examined in the book to show conflicts between guaranteeing access to medications and encouraging innovation. Offering insights on India’s strategic actions and their consequences for world pharmaceutical policies, Halliburton advocates a sophisticated approach that balances international patent commitments with public health imperatives.
Dayal, Sumer, 2014.
Examining the historic Novartis v. Union of India case and its effects on worldwide patent law, TRIPS compliance, and the dynamics between rich and developing nations, Dayal’s paper critically questions It examines how the Indian Supreme Court’s ruling changed ideas of patentability criteria, especially with relation to access to reasonably priced medications and small advances.
Villarreal, Mario, and Elizabeth DuPre, 2009
Villarreal and DuPre look at how TRIPS affects global medical access and pharmaceutical innovation. Their studies evaluate how TRIPS commitments affect patent strategy of multinational pharmaceutical companies, therefore influencing medicine availability and price in poor nations. The report suggests changes to improve innovation while guaranteeing fair access to necessary medicines, looking at legislative measures meant to balance intellectual property protections with public health obligations.
OVEREXTENDING INTELLECTUAL PROPERTY
The concept of intellectual property and its application within the contemporary patent regime are not inherently oppressive or devoid of beneficial outcomes. Legal scholar and critic of the current IP framework, James Boyle (2008), argues that intellectual property, in principle, can provide a balanced system. By granting innovators a temporary monopoly on their innovations, contingent on public disclosure of their workings, IP law strikes a balance between individual and public interests. This approach marked an improvement over earlier practices where innovators often kept their formulations secret, leading to the loss of valuable knowledge upon their death. Presently, such innovations enter the public domain after twenty years under patent law. “However, the issue arises with the overextension of IP laws and the perpetuation of myths about individual invention that underpin these laws. Scholars have highlighted that claims of individual invention often obscure the collective and incremental nature of innovation in fields like medicine, science, and the arts. For instance, patents protect the collective inventions of corporate employees primarily because a corporation is legally considered an individual, while the collective knowledge of a community or an indigenous medical system remains unpatentable.”
Prior to the World Trade Organization (WTO) era, nations had greater autonomy in crafting their IP laws, allowing for more freedom to borrow, share, and appropriate knowledge and creations across borders. Today, powerful commercial interests drive the reinforcement of patent barriers, often at the expense of less privileged forms of knowledge. This trend leads to a loss of creativity, a reluctance to share knowledge, and a shrinking public domain. Critics lament the loss of an intellectual commons, noting that the struggle over IP laws involves both powerful advocates of expansive IP law and groups resisting these expansions by making defensive claims.
In Indonesia, for example, the government’s efforts to protect indigenous knowledge and arts—ranging from contemporary theater to textiles to classical dance—through new IP laws inadvertently limit cultural exchange by restricting outside artists from borrowing Indonesian cultural elements. This restriction, though intended to defend local artists, can actually work against their interests by curtailing the circulation and use of their products by outsiders. Similarly, in India, while the nation celebrates its contributions to global patrimony—from yoga to Gandhian nonviolence to ayurvedic medicine—attempts to encode and protect these knowledge systems, such as through the Traditional Knowledge Digital Library (TKDL), could potentially stifle the discovery of new treatments for diseases.
Historically, cultural hybridity was commonplace, and the adoption and sharing of diverse cultural and scientific ideas—what might be considered forms of piracy today—were the norm. Until recently, the absence of restrictive laws allowed for an open public domain. Europeans did not pay royalties to China for innovations like pasta, tea, or fireworks, nor did mathematicians and engineers need to navigate permissions for numerical concepts sourced from India, Greece, or Arab scholars. “While restrictions on sharing knowledge and innovations may represent a loss to human creativity and scientific discovery, researchers caution against an idealized open public domain. Such an ideal often ignores social inequalities that enable more powerful interests to exploit communal resources more effectively. It is also misleading to attribute equal blame to corporate interests and defenders of local knowledge for the current partitioning of global knowledge.” Efforts to defend Ayurveda, yoga, and the arts in India, Indonesia, and elsewhere are best seen as reactions to the initial moves by corporate actors to monopolize these knowledge forms.
REACTING TO GLOBALIZATION: POWER, COMPLEXITY, AND VULNERABILITY
This research examines the dynamic struggles between activists, corporations, and government actors as they navigate the complexities of globalization. Global initiatives and agreements continuously reshape our socioeconomic landscape, and understanding and reacting to these forces—described here as “constellations” of power due to their multifaceted and intricate nature—can be challenging. WTO mandates such as the Trade-Related Aspects of Intellectual Property Rights (TRIPS), free trade agreements like NAFTA, and the proposed Trans-Pacific Partnership (which includes new IP protections), along with the constant relocation of industrial production for lower labor costs, frequently alter our world. However, discerning their long-term effects remains difficult.
This analysis of the ongoing struggle over IP claims emphasizes the legibility of power, referring to how difficult it is for those affected—be it individuals, journalists, researchers, or activists—to understand a power system like the new patent regime. Historically, analyses of power and resistance focused on more discernible power relations, where threats and their sources were clearer. For instance, labor exploitation and land seizures led to the Mexican Revolution and similar uprisings in the 20th century, and authoritarian leaders like Mussolini and Suharto presented obvious threats. Political scientist James Scott famously argued that resistance often manifests not in open revolt but in “everyday forms of resistance” like foot-dragging and work slowdowns, with clear conditions such as landlords raising rents or mechanization displacing workers.
Today, the diffuse and amorphous “forces of globalization” are harder to decipher and resist. These networks of power resemble rhizomes, a metaphor used by social scientists and philosophers to describe decentralized and non-hierarchical structures. The global IP regime, while initially implemented by a central entity like the WTO, has evolved into a rhizomatic structure, with laws changing and new supporters emerging in different countries. Some supporters, such as those in India protecting Ayurveda through the TKDL, may appear resistant but reinforce the principles of the new IP regime by preparing to challenge patents within its framework.
Social anthropologist Shalini Randeria describes the contemporary state of globalization as complex and multifaceted, involving webs of corporate and government actors and multiple legal regimes. Unlike earlier power struggles against clear adversaries like landlords or authoritarian leaders, today’s government and local officials might be allies in some contexts and adversaries in others. The current global governance architecture, characterized by diffuse and elusive power, requires navigating multiple legal regimes, including TRIPS and the Convention on Biological Diversity. Francis Gurry of the United Nations World Intellectual Property Organization (WIPO) also highlights the increasing complexity of international policies and agreements post-TRIPS, with organizations like the Convention on Biological Diversity, the Food and Agriculture Organization, and UNESCO integrating IP positions into their agendas for the first time.
The dynamics of power and resistance have been a focal point of social science research for decades. However, the diffuse nature of contemporary power—which makes it challenging to comprehend and devise effective resistance strategies—has not been central to this research. The case of India, with its rich history of medical knowledge and recent legal battles over pharmaceutical patents, exemplifies the broader global struggle to balance the protection of intellectual property with the need for accessible and affordable healthcare.
SUGGESTIONS
Policymakers should build a more balanced IP system that prioritizes public health over business interests. This can involve lowering patent terms for important treatments and enforcing mandatory licencing rules allowing the manufacturing of generic medications in response to public health crises. Encouragement of open innovation and cooperative research will help to lessen the negative effects of strong intellectual property rules.
Nations should create strong systems for the preservation of traditional knowledge that deviates from Western IP models in not only copy-paste fashion. Establishing traditional knowledge databases, such as India’s Traditional Knowledge Digital Library (TKDL), helps avoid theft and promotes an atmosphere in which traditional knowledge could support worldwide innovation.
Dealing with the worldwide issues raised by intellectual property laws calls for international cooperation. To guarantee that intellectual property laws serve the worldwide public interest, organisations such as the World Health Organisation (WHO) and the World Intellectual Property Organisation (WIPO) should be more active in helping conversation and cooperation between nations. Crucially, public awareness of how IP rules affect access to drugs and innovation is growing. Campaigns for education and advocacy help to produce a more knowledgeable public capable of actively participating in policy debates and advocating required improvements. Investigating alternate incentive systems for pharmaceutical innovation—such as prize money and advanced market commitments—may offer efficient means of boost research and development outside of depending just on patents.
Encouragement and support of local innovation ecosystems—especially in underdeveloped nations—helps to create capacity for pharmaceutical research and development. This covers funding for regional researchers and innovators as well as infrastructure and education. These recommendations help to build a more fair and sustainable IP system that advances access to necessary medications as well as innovation by means of sustainability. Not only is it a question of legal and economic policy, but also a vital first step towards reaching world health equity and creating a more inclusive innovation scene by juggling these interests.
CONCLUSION
The complex dynamics of intellectual property legislation in the pharmaceutical sector offer a careful equilibrium between guaranteeing access to necessary medications and motivating invention. Mostly controlled by strong commercial interests, the present global IP system has resulted in the strengthening of patent barriers, sometimes at the price of public health and less privileged information sources. Supported by tales of individual invention, the overextension of IP laws hides the social and incremental character of innovation, especially in sectors like medicine where corporate organisations sometimes claim patents for discoveries based on shared knowledge.
Historically, the more free knowledge and ideas were exchanged, scientific and cultural progress was encouraged. But strict intellectual property rules today endanger this flow, which results in a declining public domain and stifling of invention and creativity. Though required, the defensive actions taken by nations such as India and Indonesia to safeguard their traditional knowledge and cultural legacy reflect the general impact of international intellectual property law.
Globalization’s complexity lends still another level of challenge for negotiating these problems. For those impacted—patients, entrepreneurs, and legislators—the diffuse and sometimes opaque networks of power involved in global IP governance make it difficult to grasp and respond to the dynamics at work. These power systems’ rhizomatic character—their dispersed, non-hierarchical spread—complicates resistance attempts even more.
Examining and changing the present IP system critically can help us to solve these problems by better balancing the interests of public health with those of innovation. This calls for a change in the fundamental stories supporting the current system in addition to legislative and regulatory adjustments.
REFERENCES
- Brougher, Joanna T. Intellectual Property and Health Technologies: Balancing Innovation and the Public’s Health. Springer Science & Business Media, 2013.
- Brown, Scott, and Martine Andersson. Analyzing the efficacy of the pharmaceutical patent system. MS thesis. 2019.
- Dayal, Sumer. “Redefining patentability: The impact of Novartis v Union of India on TRIPs, trade and the balance of power between developed and developing nations.” Intellectual Property Forum: journal of the Intellectual and Industrial Property Society of Australia and New Zealand. No. 99. 2014.
- Dhar, Biswajit, and K. M. Gopakumar. “Post-2005 TRIPS scenario in patent protection in the pharmaceutical sector: The case of the generic pharmaceutical industry in India.” UNCTAD and IDRC, Geneva (2006).
- Dhar, Biswajit, and K. M. Gopakumar. “Post-2005 TRIPS scenario in patent protection in the pharmaceutical sector: The case of the generic pharmaceutical industry in India.” UNCTAD and IDRC, Geneva (2006).
- Geaghan-Breiner, Charlotte. “The patent trap: the struggle for competition and affordability in the field of biologic drugs.” Colum. JL & Soc. Probs. 54 (2020): 589.
- Halliburton, Murphy. India and the patent wars: Pharmaceuticals in the new intellectual property regime. Cornell University Press, 2017.
- Kaushik, MadhuBala, et al. “Navigating Intellectual Property Rights: Fostering Innovation, Access, and Education in the Indian Context.” E3S Web of Conferences. Vol. 399. EDP Sciences, 2023.
- Sundaram, Jae. Pharmaceutical patent protection and world trade law: the unresolved problem of access to medicines. Routledge, 2018.
- Villarreal, Mario, and Elizabeth DuPre. “Trips, pharmaceutical innovation and access to medicines.” Innovation, Employment and Growth Policy Issues in the EU and the US (2009): 189-205.
- Yadav, Sankalp, Gautam Rawal, and Madhan Jeyaraman. “India’s decision to deny an extension of patent for bedaquiline: a public health imperative.” Cureus 15.11 (2023).
Riya Kashyap
Vivekananda Institute of Professional Studies